Adamas Pharmaceuticals Inc.’s (ADMS) ADS-5102 for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease awaits FDA decision on August 24, 2017.Levodopa is the most effective therapy for Parkinson's disease and is considered the "gold standard. Over time, nearly all Parkinson's disease patients will experience levodopa-induced dyskinesia (LID) depending on their Levodopa dose.If approved, ADS-5102 will be the first and only medicine for the treatment of LID in Parkinson's disease.ADMS closed Friday's (July 28) trading at $17.66, up 0.23%.